Amarin Corporation plc has reported its financial results for the second quarter of 2025, highlighting an 8% increase in total net revenue to $72.7 million compared to $67.5 million in the same period of 2024. The company's product revenue, net, experienced a 2% decline to $46.6 million from $47.5 million in Q2 2024, with U.S. sales dropping 17% to $36.5 million. However, Europe and Rest-of-World regions saw substantial growth in product revenue, with Europe up 85% to $6.6 million and Rest-of-World surging from $0.2 million to $3.5 million. Licensing and royalties revenue rose 31% to $26.1 million. The company reported a net loss of $14.1 million for Q2 2025, a significant shift from a net income of $1.5 million in Q2 2024. Operating expenses slightly increased by 1% to $43.6 million, excluding a $22.8 million restructuring charge related to corporate restructuring in June 2025. Amarin's CEO, Aaron Berg, emphasized operational efficiency and balance sheet management, noting that restructuring efforts aim to reduce operating expenses and cash burn moving forward. The company ended the quarter with $298.7 million in cash and remains debt-free. Amarin anticipates accelerated in-market demand in Europe and aims to achieve positive free cash flow in the future, focusing on the growth and impact of its product, VASCEPA®/VAZKEPA®, globally.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.